Dermata Therapeutics, Inc. (DRMA) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$7.76M | +30.5% |
| 2024 | -$11.16M | -74.2% |
| 2023 | -$6.41M | +27.5% |
| 2022 | -$8.83M | -55.2% |
| 2021 | -$5.69M | -41.3% |
| 2020 | -$4.03M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$7.76M | +30.5% |
| 2024 | -$11.16M | -74.2% |
| 2023 | -$6.41M | +27.5% |
| 2022 | -$8.83M | -55.2% |
| 2021 | -$5.69M | -41.3% |
| 2020 | -$4.03M | — |